The role of spreading depolarizations and electrographic seizures in early injury progression of the rat photothrombosis stroke model

Karl Schoknecht1,2,3,4,5,6, Majed Kikhia3,7, Coline L Lemale1,3, Agustin Liotta4,5,8, Svetlana LUBLinsky9, Susanne Mueller1,3,10, Philipp Boehm-Sturm1,3,10, Alon Friedman9,11 and Jens P Dreier1,2,3,7,12

Abstract

Spreading depolarization (SD) and seizures are pathophysiological events associated with cerebral ischemia. Here, we investigated their role for injury progression in the cerebral cortex. Cerebral ischemia was induced in anesthetized male Wistar rats using the photothrombosis (PT) stroke model. SD and spontaneous neuronal activity were recorded in the presence of either urethane or ketamine/xylazine anesthesia. Blood–brain barrier (BBB) permeability, cerebral perfusion, and cellular damage were assessed through a cranial window and repeated intravenous injection of fluorescein sodium salt and propidium iodide until 4 h after PT. Neuronal injury and early lesion volume were quantified by stereological cell counting and manual and automated assessment of ex vivo T2-weighted magnetic resonance imaging. Onset SDs originated at the thrombotic core and invaded neighboring cortex, whereas delayed SDs often showed opposite propagation patterns. Seizure induction by 4-aminopyridine caused no increase in lesion volume or neuronal injury in urethane-anesthetized animals. Ketamine/xylazine anesthesia was associated with a lower number of onset SDs, reduced lesion volume, and neuronal injury despite a longer duration of seizures. BBB permeability increase inversely correlated with the number of SDs at 3 and 4 h after PT. Our results provide further evidence that ketamine may counteract the early progression of ischemic injury.

1Center for Stroke Research Berlin (CSB), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
2Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3Department of Experimental Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
4Neuroscience Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
5Institute for Neurophysiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
6Carl-Ludwig-Institute for Physiology, Medical Faculty, University of Leipzig, Leipzig, Germany
7Einstein Center for Neurosciences Berlin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
8Department of Anesthesiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universitäts zu Berlin, and Berlin Institute of Health, Berlin, Germany
9Departments of Physiology & Cell Biology, Cognitive & Brain Sciences, the Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel
10NeuroCure Cluster of Excellence and Charité Core Facility 7T Experimental MRIs, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
11Department of Medical Neuroscience, Dalhousie University, Halifax, Canada
12Bernstein Center for Computational Neuroscience Berlin, Humboldt-Universität zu Berlin, Germany

Corresponding author:
Jens P Dreier, Center for Stroke Research, Department of Neurology, Department of Experimental Neurology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Email: jens.dreier@charite.de

Journal of Cerebral Blood Flow & Metabolism
2021, Vol. 41(2) 413–430
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0271678X20915801
journals.sagepub.com/home/jcbfm
Keywords
Blood–brain barrier, ketamine, seizure, spreading depolarization, stroke

Received 19 November 2019; Revised 6 February 2020; Accepted 2 March 2020

Introduction
Stroke is the second-leading cause of death and the third leading cause of disability worldwide with a total cost in Europe (2010) of 64.1 billion €.1,2 There are currently no proven neuroprotective drugs that improve stroke outcomes. Fundamental challenges to advancing the treatment of stroke are its heterogeneity in terms of cause, pathology, and the lack of mechanistic endpoints in clinical studies. Mechanistic endpoints, necessary for appropriate targeting of treatment, have been lacking due to the limited ability to validate and monitor relevant pathologic processes in clinical populations. Insight into the mechanisms contributing to neural injury and the consequent development of mechanistic endpoints holds great promise to unravel the heterogeneity of stroke, assign appropriate treatment and monitor its efficacy.

Spreading depolarizations (SD) and epileptic seizures have been associated with cerebral ischemia and could serve as mechanistic endpoints.3–6 SD is characterized by the near-complete loss of the transmembrane ion-gradients and water influx (=cytotoxic edema).3,7,8 Terminal SD, observed in severely ischemic tissue, and transient SDs in less compromised or metabolically intact tissue define a continuum of spreading mass depolarizations.9,10 In patients, terminal SDs have been recorded during global cerebral ischemia in the wake of circulatory arrest11 and in regions developing new brain infarcts after aneurysmal subarachnoid hemorrhage (aSAH).5,12,13 Transient (reversible) SDs have been found in 90–100% of patients with malignant hemispheric stroke (MHS)14 and 70–80% of patients with aSAH.15 In animals undergoing severe cerebral ischemia, SD characteristically occurs at a spot in the tissue with a delay of 1 min or more following the onset of ischemia.16 From there, SD spreads against the gradients of perfusion and oxidative substrate supply into the surrounding increasingly well-perfused tissue. Whereas severely ischemic tissue often remains persistently depolarized, less ischemic and normal tissue recovers from SD. However, further SDs may develop in the ischemic penumbra in a recurring pattern that creates the characteristic pattern of temporal clustering.14,15,17 Recurrent SDs have been shown to enlarge focal ischemic brain lesions.18,19 The common upstream mechanism leading to SD is a reduction of $\text{Na}^+$/K$^+$ ATPase function relative to the demand for pump activity.3,20,21

Electrographic seizures were recorded with an incidence of up to 27% in ischemic stroke22 and 38% in aSAH patients using continuous non-invasive electroencephalographic (EEG) or invasive electrocorticographic (ECoG) recordings during the first week after the acute insult.23–26 While non-convulsive status epilepticus was associated with increased morbidity and mortality following aSAH,23 results regarding the impact of seizures on outcome after ischemic strokes have been inconsistent.4,27

Here, we compared the impact of SDs and electrographic seizures on the early lesion progression after cortical photothermolysis (PT) in rats. As a secondary outcome parameter, we measured blood–brain barrier (BBB) permeability since SDs and seizures have been shown to increase BBB permeability in animal models28–30 and increased BBB permeability predicted neurological outcome after aSAH in patients.31 To induce cerebral ischemia, we chose the well-established PT model.32 It is characterized by the generation of SDs32,33 and by lesion progression.34 Frequencies of seizures and SDs were modulated using 4-aminopyridine (4-AP, $\text{Kv1 K}^+$-channel blocker) and two different types of anesthesia, either urethane or ketamine/xylazine. To measure lesion size, cellular (and specifically neuronal) damage and vascular permeability, we used intravital microscopy,34,35 ex-vivo magnetic resonance imaging (MRI), and histopathology.

Material and methods
All experimental procedures were performed and reported according to the Animal Research: Reporting of In-Vivo Experiments (ARRIVE) guidelines, were approved by the local animal care and ethical committee LAGeSo (Landesamt für Gesundheit und Soziales, G0161/14) and complied with the Charité Animal Welfare Guidelines.

Photothermolysis model of cerebral ischemia
A total of 30 male Wistar rats (bodyweight 200–430 g (6–11 weeks old; Janvier S.A.S., Germany), housed in groups under a 12-h light-dark cycle with free access to food and water, were deeply anesthetized with
intraperitoneal injection of either urethane (1.5–1.8 g/kg bodyweight) or ketamine (80 mg/kg bodyweight) plus xylazine (12 mg/kg bodyweight). As in our previous study,34 animals underwent craniotomy over the right somatosensory cortex (2 mm frontal–4 mm occipital and 2 and 6 mm lateral to bregma) and removal of the dura. Thereafter, artificial cerebrospinal fluid (aCSF) containing (in mM) 129 NaCl, 21 NaHCO3, 10 glucose, 3 KCl, 1.25 Na2HPO4, 1.6 CaCl2, and 1.8 MgCl2 was topically applied to the brain. Oxygen saturation was continuously monitored at the hind paw (Starr Life Science MouseOx probe, Oakmont, PA, USA) and body temperature was kept at 37 ± 0.5°C using a heating pad (Harvard Apparatus, Holliston, MA, USA). PT was induced following cannulation of the tail vein, injection of Rose Bengal (0.133 ml/100 g body weight, 7.5 mg/ml saline, 9.8 μM/kg, Sigma Aldrich, St. Louis, MO, USA) and subsequent focal monochromatic illumination (532 nm, diameter of ~1 mm, MGL-III-532-5mW-1.5, CNI Laser, Changchun, China) for 15 min. Thereafter, the animal was strictly shielded from light for 1 h to prevent unspecific Rose Bengal activation. The study consisted of three main experimental groups; group 1: PT under urethane anesthesia (n = 9), group 2: PT under urethane anesthesia with topical brain surface administration of 4-AP (2 mM, Sigma Aldrich, St. Louis, MO, USA) diluted in aCSF starting 70 min after PT (i.e. after completing fluorescein sodium salt and propidium iodide imaging 1 h after PT) (n = 7), and group 3: PT under ketamine/xylazine anesthesia with brain topical administration of 4-AP (500 μM) diluted in aCSF starting 70 min after PT (n = 8). Non-ischemic animals (without PT) treated with 4-AP under ketamine/xylazine anesthesia made up a fourth experimental group to examine whether 4-AP would lead to SDs in the absence of PT (n = 6).

**Intravital fluorescence and intrinsic optical signal imaging**

The imaging-setup consisted of a fluorescence microscope (Zeiss SteReO Lumar V12; Oberkochen, Germany) and a charge-coupled device (CCD) camera (CoolSNAP HQ2, Photometrics, Tucson, AZ 85706, US). Images were captured at ×6.4–×35 magnification and quantitative analysis was performed on ×35 magnification images. Perfusion and BBB permeability assessment were based on intravenous injections of fluorescein sodium salt (1 mg/kg body weight, 1 mg/ml saline, Sigma Aldrich, St. Louis, MO, USA) pre-PT and hourly following PT. Images were taken at 5 Hz for 306 s starting 6 s prior to dye injection. Propidium iodide (Molecular Probes, Eugene, OR, USA; 0.5 mg/kg body weight, 0.5 mg/ml saline) was intravenously injected before and hourly after PT. Quantitative image analysis of propidium iodide was based on an averaged image (consisting of 10 frames, acquisition rate: 1 Hz) acquired 10 min after propidium iodide injection. Intrinsic optical signal (IOS) was visualized by subtracting bright-field images pre-SD from subsequent brightfield images during SD.

**Electrophysiological recordings and laser-Doppler flowmetry**

Ion-sensitive microelectrodes inserted to a depth of 200–300 μm from the brain surface were used to simultaneously record direct current electrocorticography (DC-ECoG) and the extracellular potassium concentration ([K+]o). Electrodes were built in-house from double-barreled theta-glass. The reference side contained 154 mM sodium chloride (NaCl) and the ion-sensitive side contained Potassium Ionophore I 60031 (Fluka, Buchs, Switzerland) at the tip and was filled with 100 mM potassium chloride (KCl) as described previously.36 Electrical potentials were converted to K+ concentrations using Nernst’s equation and assuming baseline levels of 3 mM [K+]o. A Power 1401 served for analog-to-digital conversion and Spike 2 software (both Cambridge Electronic Design Limited, Cambridge, UK) was used for recording. Regional cerebral blood flow (rCBF) was continuously recorded using a laser-Doppler probe (Periflux System 5000, Perimed, Järffalla, Sweden) placed on the peri-lesional cortex.

**Ex vivo MRI**

At the end of the experiment, animals were perfusion-fixed with 4% paraformaldehyde (PFA). Brains were removed and stored in phosphate-buffered saline (PBS) containing 0.4% PFA. T2-weighted MRI was performed on brains stored in PBS at 7 Tesla (Bruker BioSpec, Ettlingen, Germany) using an 86 mm volume resonator for transmission, a rat brain surface coil for signal reception (Rapid Biomedical GmbH, Rimpar, Germany), Bruker Software (Paravision 6.0.1) and a 2D T2-weighted pulse sequence (2D RARE, repetition time = 8500 ms, echo time = 31.20 ms, rare factor 8, 12 averages, 84 contiguous axial slices per 0.25 mm, field of view 25.6 mm × 25.6 mm, in plane solution 256 × 256; scan time 54 min 24 s). Lesion volume was quantified by two independent approaches of summing up hyperintense voxels in comparison with the contralateral hemisphere: (1) by manually outlining the lesion border in a blinded fashion using Analyze software (AnalyzeDirect, Inc., Stilwell, KS, USA) (performed by KS) and (2) by automated segmentation using an
in-house build MATLAB algorithm (MathWorks Inc., Natick, MA, USA) (performed by SL).

**Histology**

Following MRI, brains were transferred to cryoprotection solution containing 30% sucrose. Brains were cut in 20 μm thick coronal slices with a cryostat (Leica CM 1950, Wetzlar, Germany) and stained with hematoxylin and eosin following dehydration with increasing ethanol concentration. A Leica DMRA fluorescence microscope (Leica Microsystems, Wetzlar, Germany) with a two-axis computer-controlled stepping motor specimen stage and a CCD camera (Retiga 2000 R, QImaging, Surrey, Canada), as well as the Stereo Investigator 10 software (Microbrightfield Inc., Williston, VT, USA) served for blinded stereological assessment of neuronal damage. Counting was performed under a 40× oil immersion objective by MK and CL. The analyzed region of interest (ROI) included the entire photothrombotic gray matter lesion. In all experiments, the ROI was selected as the ipsilateral gray matter superior to a tangent line through the top of the corpus callosum in each counted slice (Figure 6(b)). The counting of injured neurons was based on their morphological changes following ischemia. These changes include the loss of cytoplasmatic basophilic structures, the shrinkage of the perikaryon into a triangular shape, the presence of edematous changes in the surrounding extracellular space, and the fading or disappearing nucleolus. An injured neuron was defined as a cell lacking a nucleolus with acidophilic cytoplasm, and a shrunken perikaryon surrounded by edematous extracellular space (Figure 6(c)). We sampled nine slices per brain across the lesion (i.e. one slice every 160 μm), with a counting frame size of 50 × 50 μm and a grid size of 250 × 250 μm (i.e. counting only one 50 × 50 μm frame within each 250 × 250 μm square of the grid). This amount of sampling was sufficient to reach a coefficient of error <0.05, which indicates sufficient reliability of the stereological count estimate.

**Data and image processing**

Electrophysiological and imaging data were analyzed using MATLAB. Low-pass filtering (0.5 Hz, DC-signal), band-pass filtering (0.5–45 Hz, alternate current (AC)), and signal power calculation (AC-power) were achieved with build-in functions. Imaging data were corrected for movement artifacts. Relative perfusion, BBB permeability, and cellular damage were quantified as described previously. In brief, repeated intravenous fluorescein sodium salt injections and parallel surface imaging were used to estimate perfusion and BBB permeability. First-pass kinetics were used to identify hypoperfused pixels by setting a threshold of 30% of a selected arterial input function (AIF), i.e. the maximal intraarterial first pass image intensity. A pixel-based BBB permeability index was calculated by dividing the integral of the fluorescein signal (excluding the first pass) of each pixel by the time-matched integral of the AIF. Cellular damage was quantified as the number of propidium iodide-positive pixels following background correction by low-pass filtering of the image. BBB permeability and cell damage were assessed as functions of distance to a circular estimate of the lesion border based on the 1 h post-PT angiography.

**Experimental design and statistical analysis**

This is an exploratory study. No prior information was available which would have enabled us to perform sample size estimations based on evidence. We thus chose sample sizes which are standard in the field. Animals were excluded in cases of insufficient surgical quality, i.e. if BBB dysfunction or cell damage were detected prior to PT induction. This allowed inclusion of 30 animals to the study. Animals under urethane anesthesia were randomly assigned to 4-AP treatment following PT induction. In vivo imaging data, neuronal cell death, and MRI-based lesion volume were analyzed blindly. For statistical inference, non-parametric Wilcoxon signed-rank test, Mann-Whitney U test or Kruskal–Wallis test (>2 groups) were utilized. Correlations were expressed as Spearman coefficients (rho). Differences were considered significant at \( p \leq 0.05 \). Data are shown as median and interquartile range (IQR), i.e. 25th and 75th percentile.

**Results**

**PT rapidly elicits SDs but no seizures**

PT, i.e., intravenous injection of Rose Bengal and simultaneous neocortical dye activation with green (532 nm) laser light, resulted in rapid occlusion of blood vessels at the site of illumination (Figure 1(a)). To measure electrographic seizures and SDs, two electrodes were placed at a distance of 340 (IQR: 150–470) μm (\( n = 24 \)) and 870 (550–1100) μm (\( n = 21 \)) from the lesion border (Figure 1(a)). The study consisted of three main experimental groups; group 1: PT under urethane anesthesia (\( n = 9 \), Figure 1), group 2: PT under urethane anesthesia with 4-AP administered topically 70 min after PT (\( n = 7 \), Figure 2), and group 3: PT + 4-AP under ketamine/xylazine anesthesia (\( n = 8 \), Figure 3). SD was recorded in all animals and the first SD occurred at a median of 5.6 (4.6–7.3) min following Rose Bengal injection under urethane anesthesia.
Figure 1. Photothrombosis (PT) model and recordings under urethane anesthesia. (a) Arterial phase of fluorescent angiography prior to PT induction (left), laser spot to activate i.v.-injected Rose Bengal (middle) and fluorescent angiography illustrating occluded vessels in the previously laser-illuminated area (right). Circular dotted line marks lesion border, colored dotted lines overlie the two ion-sensitive glass electrodes. E1: electrode 1; E2: electrode 2. (b) Recordings of one PT experiment under urethane anesthesia from E1 (closer to PT lesion, blue) and from E2 (orange). Each SD (see for example *) displays a transient direct current (DC) potential change (DC-ECoG), a power reduction (alternate current (AC)-power), and a characteristic increase in $[K^{+}]_o$. SDs induce a hyperemic blood flow response. At higher temporal resolution, the delay of the SD onset between E1 and E2 becomes visible. Note how the initial SD (*) was first recorded at E1, whereas the third SD (**) approximately 84 min after PT was first recorded at E2. (c) Intrinsic optical imaging (IOS) illustrates how the SD wavefront of the third SD originates in peri-thrombotic tissue and propagates towards primarily thrombotic tissue.
and was termed onset SD because of the close temporal proximity to PT induction. In 13 of 16 animals (groups 1 and 2), the onset SD was followed (within minutes) by up to four additional SDs to form an onset complex of SDs (Figure 4(a) and (b)). SDs were identified by their typical features: a negative DC potential shift, a concomitant rise in $[K^+]_o$, and depression of the AC-ECoG activity in electrically active tissue (=spreading depression). Onset SDs originated at the thrombotic region and invaded the surrounding cortex. SDs were termed delayed SDs from the start of 4-AP perfusion in groups 2 and 3. Accordingly, all SDs starting later than 70 min after PT induction were termed delayed SDs in group 1, wherein no 4-AP was administered. In animals that displayed delayed SDs, they spread in reverse direction (i.e. from the periphery to the thrombotic center) in 12 out of 16 experiments (pooled experimental groups) as revealed by the electrophysiological recordings and IOS imaging (Figure 1(c)). Spontaneous seizures were not recorded in any of the animals during the 4 h monitoring after PT under urethane anesthesia in group 1 or in any of the animals during the first 70 min before 4-AP perfusion under either urethane or ketamine/xylazine anesthesia (groups 2 and 3).

4-AP-induced electrographic seizures show smaller DC-amplitudes and peak $[K^+]_o$-levels than SDs

To test the effect of seizures on injury progression, we applied the convulsant Kv1 $K^+$-channel blocker 4-AP starting 70 min after PT in groups 2 and 3.
4-AP application resulted in a gradual increase in AC-ECoG power that eventually turned into distinct recurrent seizures (Figure 2(a)). The maximal negative DC-shift as well as the peak $[K^+]_o$ levels during electrographic seizures were significantly smaller than during SDs (seizures: $-3.7 \pm 1.0$ (5.5–(−23.3)) mV and 9.1 (7.5–11.1) mM vs. SDs: $-21.1 \pm 9.1$ (−22.8–17.2) mV and 39.5 (36.2–44.4) mM; negative DC-shift and peak $[K^+]_o$ respectively, $n = 10, p = 0.005$, Wilcoxon signed-rank test, pooled data from groups 2 and 3, Figure 4(d) and (e)). $[K^+]_o$ between recurrent SDs and/or seizures increased from 3 to 4.5 (4.0–6.5) mM during the fourth hour of recording (all groups, $n = 19, p < 0.001$, Wilcoxon signed-rank test) without significant differences between seizing (groups 2 and 3) and seizure-free (group 1) animals ($p = 0.45, n = 10;9$, Mann–Whitney U test). Return of $[K^+]_o$ to pre-SD levels was slower or less complete after delayed SDs than after onset SDs (Figures 1 to 3).

**Suppression of SD and lower seizure threshold under ketamine**

To investigate the effect of SD on injury progression, animals were anesthetized with ketamine and xylazine in group 3 (Figure 3), since ketamine was previously shown to block propagation and, at higher doses, initiation of SDs. Under ketamine, SDs were still recorded in all animals (Figure 4(c)), yet the latency to the first SD following PT was significantly longer compared with animals under urethane anesthesia (group 3: 9.1 (7.2–35.9) min, $n = 8$, vs. pooled groups 1 and 2: 5.6 (4.6–7.3) min, $n = 16, p = 0.027$, Mann–Whitney U test, Figure 4(g)). Further, the number of onset SDs was lower under ketamine (group 3: 1 (1–2) SD, $n = 8$, vs. pooled groups 1 and 2: 3 (2–5) SDs, $n = 16, p = 0.007$, Mann–Whitney U test, Figure 4(h)). The number of delayed SDs was similar in all groups (group 1: 1 (0–4), $n = 9$, group 2: 1 (0.25–2), $n = 7,$
Figure 4. Quantitative seizure and SD analysis. (a–c) Each line represents an animal/experiment and each dot represents a singular SD. Note that onset SDs are less frequent under ketamine/xylazine anesthesia. (d–e) Maximal DC-shift amplitudes (d) and maximal \([K^+]_o\) levels (e) are larger during SDs than during seizures (pooled data from groups 2 and 3, \(n = 10\), Wilcoxon signed-rank test). (f) The rCBF response to delayed SDs is smaller than to onset SDs (pooled data from groups 1–3, \(n = 13\), Wilcoxon signed-rank test). Early and late seizures evoke similar hyperemic rCBF responses that are smaller than rCBF responses for onset SDs (pooled data from groups 2 and 3, \(n = 12\), Wilcoxon signed-rank test). (g) The time to the first SD after PT is prolonged under ketamine anesthesia (groups 1 and 2 vs. group 3, \(n = 16\) and 8 respectively, Mann–Whitney U test). (h) The number of onset SDs is lower under ketamine/xylazine anesthesia (groups 1 and 2 vs. group 3, \(n = 16\) and 8 respectively, Mann–Whitney U test). (i) The number of delayed SDs is not different across groups (\(n = 9\), Kruskal–Wallis test). (j) The time to the first seizure is shorter under ketamine/xylazine anesthesia (\(n = 7\) and 8, Mann–Whitney U test). (k–l) The cumulative seizure duration (K) and seizure power (L) are higher under ketamine/xylazine anesthesia (\(n = 7\) and 8, Mann–Whitney U test).
The seizure threshold was lower under ketamine/xylazine anesthesia than under urethane. While topical application of 4-AP at a concentration of 500 μM reliably induced recurrent seizures under ketamine (see also Prager et al.30), under urethane anesthesia, recurrent seizures were inducible only at 2 mM 4-AP and the latency to a first seizure after application of 4-AP was longer (urethane (group 2): 51.1 (38.0–58.9) min, n = 7, compared with ketamine (group 3): 18.5 (17.4–24.6) min, n = 8, p = 0.003; Mann–Whitney U test, Figure 4(j)). Cumulative seizure duration and power were higher under ketamine than urethane (ketamine (group 3): 19.1 (15.3–21.9) min and 1.02 (0.88–4.88) × 10^6 mV^2 s, n = 8, vs. urethane (group 2): 12.5 (8.0–16.8) min and 0.13 (0.12–1.16) × 10^6 mV^2 s, n = 7, p = 0.026 and p = 0.05, Mann–Whitney U tests, Figure 4(k) and (l)). Following 4-AP, SDs were often coupled with seizures and interrupted seizure activity (Figure 3(a) and (c)). No SDs were recorded when 4-AP was applied under ketamine anesthesia without prior PT induction (non-ischemic animals, n = 6).

**Reduced rCBF responses to delayed SDs, but not to seizures**

The blood flow response to SD (measured by LDF located near the lesion) was characterized by hyperemia. Regional CBF increased by 280 (242–382)% compared to pre-PT baseline during onset SDs. Hyperemia was reduced to 173 (111–297)% (p = 0.028, n = 13, Wilcoxon signed-rank test, pooled data from groups 1 to 3, Figure 4(f)) in response to SDs recorded during the last (i.e. 4th) hour of recording. In contrast, rCBF increases during seizures were smaller and similar between the first and the last recorded seizures (LDF early seizure: 143 (117–188)%; late seizure: 136 (105–173)% (n = 12, p = 0.43, Wilcoxon signed rank test, pooled data from groups 2 and 3, Figure 4(f)).

**Intravital microscopy reveals progressive hypoperfusion, increased BBB permeability and cellular damage**

To quantify lesion progression, we measured perfusion, BBB permeability and cell damage using intravital microscopy. Fluorescein-based angiography demonstrated complete arterial and venous occlusion in the laser-illuminated cortical region (Figure 5(a)). As time progressed, the initial perfusion deficit (as defined 1 h after PT) expanded into primarily well-perfused cortex (Figure 5(a) and (d)). Extravasation of i.v.-injected fluorescein indicated increased BBB permeability (Figure 5(b) and (e)). Concomitantly, the propidium iodide signal increased in the cortical area surrounding the primary perfusion deficit (Figure 5(c) and (f)). Neither perfusion nor BBB permeability were different between groups (Figure 5(g) and (h)), yet a trend towards a reduced propidium iodide signal was observed under ketamine (p = 0.06, Kruskal–Wallis; Figure 5(i)). The propidium iodide signal after 4 h as measured directly at the recording site (diameter of 100 μm around the electrode tip) did not correlate with the number of SDs, but with the counted injured neurons (see next paragraph) for electrodes located <400 μm from the lesion border (Spearman’s rho = 0.58, p = 0.040, n = 14). No correlation was found for more remote electrodes (Spearman’s rho = 0.24, p = 0.363, n = 17). The 400 μm distinction is based on perfusion data, i.e. this is the zone which was shown to undergo early progressive hypoperfusion in our previous study.34 Interestingly, BBB permeability negatively correlated with the number of SDs at 3 and 4 h after PT when data from all three groups were pooled (Spearman’s rho = −0.57 and −0.55, p = 0.004 and 0.009, n = 23, Figure 5(j)). No correlations were found between BBB permeability and the number of seizures, cumulative seizure power or accumulation of [K⁺]o in the 4-h-monitoring period after PT.

**Ketamine anesthesia was associated with reduced lesion size and neuronal damage**

To assess cortical lesion volume and neuronal damage, brains were removed ~4.5 h after PT. On manually segmented ex-vivo T2-weighted MRI (Figure 6(a)), animals with 4-AP-induced seizures under urethane anesthesia did not show an increased lesion size (number of hyperintense voxels ipsi- vs. contralateral) compared to seizure-free animals (group 2: 12.1 (11.0–16.8) mm³, n = 6, vs. group 1: 12.9 (10.7–16.2) mm³, n = 7). In contrast, lesion size was reduced to 5.3 (4.8–8.0) mm³ in animals under ketamine anesthesia (group 3, n = 7, p = 0.03; Kruskal–Wallis test, Figure 6(b)) despite the occurrence of seizures. To validate manual lesion volume measurements, we employed an automated approach for detection of hyperintense voxels and found a positive correlation between these two independent approaches (Spearman’s rho 0.61, p = 0.005, n = 20). Blind stereological counting of apoptotic/necrotic neurons (see Methods and Figure 6) revealed similar neural injury in the cortex of animals under urethane anesthesia with or without seizures (group 1: 3.68 (3.04–4.20) × 10⁵ and group 2: 3.89 (3.09–5.60) × 10⁵ counted neurons), whereas the number of injured neurons was lower under ketamine anesthesia (group 3: 2.65 (2.12–2.86) × 10⁵ neurons, p = 0.016, Kruskal–Wallis test, n = 8;7;7 animals, Figure 6(d)).
Figure 5. In-vivo imaging of cerebral perfusion, BBB permeability, and propidium iodide.

(a) Arterio-venous overlay of fluorescent angiography before and 1–4 h after PT. Note that the hypoperfused (dark) area grows with time. (b) Fluorescein extravasation relative to the intravascular tracer signal reveals a growing area with BBB dysfunction between 1 and 4 h after PT. (c) Propidium iodide (PI) staining reveals a growing number of cells with membrane damage. Scalebar = 200 μm. (d) Graphical illustration of the hypoperfused area relative to the primary lesion shows a growing perfusion deficit. (e) Similarly, the amount of tissue affected by BBB dysfunction and (f) the propidium iodide-positive area grows with time. (g–i) Quantitative analysis shows no difference in perfusion and BBB permeability across groups and a trend towards reduced propidium iodide-signal (n = 9,7,7, Kruskal–Wallis test) under ketamine/xylazine anesthesia. (j) BBB permeability inversely correlates with the number of SDs at 3 and 4 h after PT.
MRI-based lesion volume assessment correlated with stereological cell counts (Spearman’s rho = 0.71, p = 0.0005, n = 20, Figure 6(c)).

**Discussion**

In the present study, we compared the impact of the two network pathologies – SDs and electrographic seizures – on early ischemic lesion progression. Combining electrophysiological measurements with in-vivo imaging of cerebral perfusion, BBB permeability and cellular injury as well as ex-vivo assessment of lesion size (MRI), and neuronal injury (histopathology), we found that: (1) SDs abundantly occur following PT; (2) ketamine anesthesia was associated with reductions of (a) onset SDs, (b) early lesion volume and (c) early neuronal injury; (3) seizures did not occur spontaneously in presence of the antiepileptic drugs urethane and ketamine; (4) when pharmaco logically triggered by 4-AP, seizures did not alter BBB permeability, propidium iodide signal, MRI-proven lesion volume or histopathological neuronal injury; and (5) BBB permeability negatively correlated with the number of SDs at 3 and 4 h after PT induction.

SDs are common in the PT model.\(^{33}\) In a longitudinal in-vivo MRI study of this model in rats, they were associated with reductions of the apparent diffusion coefficient (ADC), indicating cytotoxic edema.\(^{41}\) The ADC reduction became rapidly irreversible in the illuminated thrombotic cortex and was progressively

---

**Figure 6.** Ex-vivo assessment of lesion volume and neuronal damage. (a) Sagittal and coronal section of ex vivo T2-weighted MRI with arrowheads pointing to the thrombotic lesion. (b) Hematoxylin and eosin staining of coronal section. Yellow line shows the region of interest (ROI) used for stereological cell counts. Arrowheads point to the thrombotic lesion. (c) Illustration of morphological criteria used to count injured neurons. A neuron with oval perikaryon, a nucleolus and homogenous extracellular matrix (1). Dark perikaryon and loosened extracellular space (2). Dark and shrunk perikaryon in edematous extracellular space (3). Triangular, dark and shrunk perikaryon in edematous extracellular space (4) Neurons fulfilling criteria 3 and 4 were counted as injured. (d) MRI-based lesion volume was reduced under ketamine/xylazine anesthesia compared with the seizure-free urethane group (n = 7;6;7, Kruskal–Wallis test). (e) Fewer injured neurons were counted under ketamine/xylazine anesthesia compared with animals under urethane anesthesia and induction of seizures (n = 8;7;7, Kruskal–Wallis test). (f) MRI-based lesion volume assessment correlated with stereological counts of injured neurons.
irreversible in a surrounding rim of tissue, which is regarded as the ischemic penumbra in the PT model (cf. literature for the discussion of penumbra definitions). Hence, in addition to many other models and recent clinical data, also the PT model has provided evidence for van Harreveld’s original hypothesis, as reviewed recently, that SD is the electrophysiological correlate of the cytotoxic edema in the brain’s gray matter. The present study confirms earlier results that characterized the ischemic penumbra as a growing region of local hyperperfusion with progressive dysfunction of the BBB. The observation that delayed SDs typically originated from initially non-ischemic, peri-thrombotic tissue further supports on-going lesion progression. A previous MCAO study in mice found that such delayed SDs depended on transient worsening of mismatch between oxidative substrate supply and demand. Such transient worsening could result not only from systemic arterial blood pressure fluctuations but also, for example, from local neuronal activation in the unstable tissue. Another observation indicating progressive metabolic compromise was the prolonged duration of delayed SDs compared with onset SDs accompanied by a slower normalization of [K+]o, after the delayed SDs and increasingly elevated baseline levels of [K+]o between recurrent SDs or seizures. The elevated baseline level of [K+]o, in turn, reduces the activity of the x2/x3 portion of the sodium-potassium ATPase. This might additionally contribute to the prolongation of SDs and SD-related cytotoxic edema, thereby facilitating lesion progression.

Consistent with the inextricable connection between SD and cytotoxic edema, we found a lower number of onset SDs associated with a smaller lesion volume and less extensive neuronal injury at sacrifice after 4.5 h in ketamine/xylazine versus urethane-anesthetized rats. Ketamine is a non-competitive antagonist of the ionotropic N-methyl-D-aspartate receptor (NMDAR) with an SD-inhibiting effect both in lissencephalic and gyrencephalic animals. In addition, high-dose S(+)-ketamine, the two times stronger, active enantiomer of ketamine, improved neurological outcome following incomplete cerebral ischemia due to combined right common carotid artery occlusion and hemorrhagic hypotension in rats. High-dose S(+)-ketamine also reduced cortical neuronal cell loss at sacrifice six days after global forebrain ischemia in rats. In our experiments, xylazine, an alpha 2 adrenergic agonist, may have exerted additional neuroprotective effects.

MK-801, another non-competitive NMDAR antagonist, has been studied more extensively than ketamine. It acts at the same binding site but is more potent. Accordingly, MK-801 also inhibits SDs in rats, as shown for KCl-triggered SDs propagating through naive tissue, but also for SDs induced by either MCAO or brain topical application of the vasoconstrictor endothelin-1. In parallel, MK-801 protects from ischemic damage as summarized in a recent meta-analysis. There are, however, a number of caveats. According to a previously described dose–response curve for neuroprotection by MK-801, lower doses (0.5 and 1 mg/kg body weight i.p.) protected from ischemic damage in some, but not all studies, whereas a medium-dose of MK-801 (3 or 5 mg/kg body weight intra-peritoneally (i.p.)) robustly reduced ischemic lesion volume when measured at sacrifice either 3 or 24 h after MCAO in rats and 6 h after MCAO in cats. Importantly, low-dose treatment with MK-801 blocked the spread of SDs into the adequately supplied surrounding tissue, but failed to inhibit SDs in the ischemic penumbra and did not protect from ischemic damage. Not only a sufficient dosage, but also the anesthetic, against which NMDAR antagonists are tested, can complicate the interpretation of the results. The neuroprotective effect might be rather small or absent when ketamine or MK-801 are tested against isoflurane, which competitively inhibits NMDARs at the glycine site, suppresses SDs, increases rCBF, and presumably for these reasons isoflurane is also neuroprotective.

A clear limitation of the treatment with NMDAR antagonists is that they cannot block terminal SD in severely ischemic tissue even at the highest concentrations and are thus unable to protect this tissue. One potential explanation is the additional involvement of non-NMDA glutamate and GABA receptors in SD during severe ischemia. In the ischemic penumbra, NMDAR antagonists can only partially inhibit SDs at high doses. Accordingly, onset SDs occurred less frequently after PT when ketamine was administered than when urethane was administered. Nevertheless, onset SDs still occurred under ketamine. Regarding the relative resistance of the penumbra to NMDAR antagonists, it is interesting to note that the progressive increase of the baseline [K+]o level alone into a range typically observed in the ischemic penumbra was sufficient to render SDs increasingly resistant to MK-801.

The main practical problem of NMDAR antagonists such as MK-801 or ketamine is that they lead to psychosis at lower and to coma at higher doses at which they partially inhibit SDs in the penumbra and therefore are neuroprotective. Avoiding psychosis and maintaining wakefulness are, without doubt, important goals in alert patients with stroke, restricting treatment of this patient population to low doses of NMDAR antagonists, at which they do not inhibit SDs in the penumbra. Accordingly, the ensuing clinical trials which exclusively investigated the effect
of low doses showed neither significant benefit nor harm from NMDAR antagonists.83,84

The renewed interest in NMDAR antagonists is now derived from two parallel clinical developments. First, ketamine has found its way into routine neurocritical care practice as a second-line combination treatment together with the GABA<sub>A</sub> agonist midazolam to sedate patients with severe acute cerebral injuries. In this patient population, ketamine is often administered at higher doses because of its beneficial cardiocirculatory and bronchodilatory properties.85,86 Second, ketamine has been associated with a decrease in SD incidence in a mixed population of 60 patients with traumatic brain injury (TBI), 31 patients with aSAH and 24 patients with malignant hemispheric stroke.87

The first prospective controlled trial of ketamine for SD inhibition recently confirmed this observation in eight patients with TBI and two with aSAH.88,89 In addition, a case-report of spontaneous intracerebral hemorrhage demonstrated suppression and reappearance of a cluster of SDs in response to intermittent ketamine treatment.90 In a recent case series of 66 aSAH patients, low- and high-dose administration of s-ketamine was retrospectively compared. The high-dose range was above the upper limit for sedation recommended by the manufacturer but resulted in further significant decrease in SD incidence.91 The present experimental study provides further support for the use of ketamine and midazolam—rather than propofol and midazolam— as first-line combination treatment in neurocritical care when clusters of SDs are recorded, as it suggests that ketamine inhibits SDs in the penumbra and is neuroprotective on this account. Notwithstanding its challenges, this concept should be further tested in a neuromonitoring-guided, randomized, multicenter clinical trial.

In addition to SDs, electrographic seizures could be a therapeutic target to reduce neuronal damage after ischemia. In the rat MCAO model, electrographic seizure rates within the first hour ranged between 28 and 81% under isoflurane and halothane anesthesia, respectively.5,93 In the neocortical PT model, hippocampal seizures were recently recorded in 66% of the rats during the first week.94 However, we did not detect electrographic seizures during the 4-h monitoring period, unless the proconvulsant 4-AP was given. This could be due to intrinsic differences between the MCAO and the PT model. Especially transient MCAO models create a large volume of penumbral tissue, whereas the PT model is characterized by a more rapidly evolving ischemic core surrounded by only a small penumbra. This may be related to differences in collateral perfusion.34,95 Consequently, in the acute phase after MCAO, there may be more vital yet dysfunctional tissue showing aberrant (epileptic) network activity. In addition, antiepileptic properties of both urethane and ketamine, which were shown to inhibit epileptic activity in animal models,96–103 have likely prevented seizures in our experiments. Specifically in the 4-AP model (given i.p.), ketamine prevented generalized tonic-clonic seizures in ~40% of the animals and delayed their onset in the remaining animals.103 In patients, ketamine has been successfully used as a third- or fourth-line treatment of refractory status epilepticus.104–106 In the present study, animals under urethane anesthesia showed a higher threshold for seizure induction by 4-AP than animals under ketamine, indicating stronger antiepileptic properties of urethane than ketamine at typical anesthetic doses.

In the present animal study, artificial induction of seizures during the early time window had no effect on early ischemic lesion progression. The early sacrifice at 4.5 h after onset of PT is a limitation of our study as the final lesion size was not evaluated and harmful effects of seizures may not become apparent until later. Another limitation is that we could not investigate the effect of seizures or SDs on lesion progression in the absence of an anesthetic.

As a secondary outcome variable, we investigated BBB permeability. Increased BBB permeability is associated with poor outcome in several brain disorders including, for example, aSAH.31 Consistent with previous studies that found BBB dysfunction as early as 5 min after PT in the thrombotic core,34,109,110 we observed early BBB dysfunction at 1 h (the earliest investigated timepoint), i.e. several hours earlier than after MCAO.111–114 This is likely explained by the different mechanisms of stroke induction in these models. PT involves the generation of free radicals during Rose Bengal activation which leads to rapid damage to the endothelium in the thrombotic core.109 However, whether free radicals are involved in the further progression of BBB dysfunction in the peri-thrombotic tissue is less clear. Thus, topical application of a free radical scavenger in combination with an inhibitor of nitric-oxide synthase 30 min after PT did not reduce the expansion of BBB dysfunction into peri-thrombotic tissue.34 This may suggest different mechanisms of BBB dysfunction in the thrombotic core and peri-thrombotic tissue. However, upregulated transcytosis seems to be the common pathway of BBB dysfunction in both thrombotic core and peri-thrombotic tissue. This was evidenced by protein-tracer detected in endothelial cells 5 min after PT in the core and by an increased number of endothelial caveolae and vacuoles 3 h after PT in peri-thrombotic tissue while tight junctions were mainly intact.115 Opening of the transcellular before the paracellular pathway also occurs after MCAO and in response to many other challenges.
such as, for example, intracarotid injection of mannitol or brain topical dehydrocholate.\textsuperscript{117}

In a study in non-ischemic cortex of mice and rats exposed by bilateral craniotomy, pinprick-induced SDs led to ipsilateral Evans blue extravasation after a delay of 3 h. This was attributed to paracellular leakage mediated by degradation of tight junction proteins by matrix-metalloproteinase 9.\textsuperscript{29} In another study in mice, SDs induced caveolin-dependent tranacellular extravasation of Evans blue remote from the site of KCl application with a delay of 6 h.\textsuperscript{28} Hence, BBB dysfunction in peri-thrombotic tissue occurs 2–5 h earlier than following SDs in the described non-ischemic animals. This suggests that early BBB dysfunction is triggered by mechanisms other than SD. In line with this conclusion, BBB dysfunction after PT, as assessed by gado-fluorine M-enhanced MRI was unaltered by treatment with MK-801.\textsuperscript{110}

Incidentally, we found a negative correlation between the number of SDs and the increase in BBB permeability 3 and 4 h after PT. The increase in BBB permeability in the penumbra causes accumulation of proteins such as albumin in the extravascular extracellular space. Following Gibbs–Donnan forces, this should lead to the uptake of water into the extracellular space. The larger extracellular space should dilute ions, metabolites, and neuroactive substances released from the cells\textsuperscript{118} and this could possibly protect against further SDs.\textsuperscript{7}

**Conclusion**

ECoG neuromonitoring in patients provides the option for early treatment stratification according to SDs detected in real time, and then to record the response to a neuroprotective intervention. A pressing clinical question is whether sedation-requiring patients displaying clusters of SDs in the wake of acute cerebral injuries should receive a combination of sedatives including ketamine in order to inhibit SDs in the penumbra. The present results in the photothrombosis stroke model provide further momentum to test this concept in a neuromonitoring-guided, randomized, blinded, multicenter, feasibility trial.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Deutsche Forschungsgemeinschaft (DFG HE 1128/18, DFG DR 323/5-1, DFG DR 323/10-1), NeuroCure EXC 257/2 Flexfund, FP7 no 602150 CENTER-TBI and Era-Net Neuron EBio2.

**Acknowledgements**

This manuscript is dedicated to Prof. Uwe Heinemann who inspired us with his unique enthusiasm for research and teaching. We are thankful for technical assistance by Tanja Specowius.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Authors’ contributions**

KS, JPD and AF designed the experiment. KS and AL conducted the in-vivo experiments. MK and CL performed histological analysis. KS, SM, SL and PBS performed and analyzed the MRI. KS, JPD and AF wrote the manuscript.

**ORCID iDs**

Karl Schoknecht https://orcid.org/0000-0002-9904-9773
Majed Kikhia https://orcid.org/0000-0002-7719-9455
Philipp Boehm-Sturm https://orcid.org/0000-0001-8777-4823
Jens P Dreier https://orcid.org/0000-0001-7459-2828

**References**

1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197–2223.

2. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155–162.

3. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011; 17: 439–447.

4. Camilo O and Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35: 1769–1775.

5. Lucell J, Lemale CL, Kola V, et al. The negative ultraslow potential, electrophysiological correlate of infarction in the human cortex. Brain 2018; 141: 1734–1752.

6. Dijkhuizen RM, Beekwilder JP, Van Der Worp HB, et al. Correlation between tissue depolarizations and damage in focal ischemic rat brain. Brain Res 1999; 840: 194–205.

7. Dreier JP, Lemale CL, Kola V, et al. Spreading depolarization is not an epiphenomenon but the principal mechanism of the cytotoxic edema in various gray matter structures of the brain during stroke. Neuropharmacology 2018; 134: 189–207.

8. Hinzman JM, DiNapoli VA, Mahoney EJ, et al. Spreading depolarizations mediate excitotoxicity in the development of acute cortical lesions. Exp Neurol 2015; 267: 243–253.

9. Dreier JP and Reiffurth C. The stroke-migraine depolarization continuum. Neuron 2015; 86: 902–922.
10. Hartings JA, Shuttleworth CW, Kirov SA, et al. The continuum of spreading depolarizations in acute cortical lesion development: examining Leito’s legacy. *J Cereb Blood Flow Metab* 2017; 37: 1571–1594.

11. Dreier JP, Major S, Foreman B, et al. Terminal spreading depolarization and electrical silence in death of human cerebral cortex. *Am Neurol* 2018; 83: 295–310.

12. Hartings JA, York J, Carroll CP, et al. Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. *Brain* 2017; 140: 2673–2690.

13. Oliveira-Ferreira AI, Milakara D, Alam M, et al. Experimental and preliminary clinical evidence of an ischemic zone with prolonged negative DC shifts surrounded by a normally perfused tissue belt with persistent electrocorticographic depression. *J Cereb Blood Flow Metab* 2010; 30: 1504–1519.

14. Dohmen C, Sakowitz OW, Fabricius M, et al. Spreading depolarizations occur in human ischemic stroke with high incidence. *Ann Neurol* 2008; 63: 720–728.

15. Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. *Brain* 2006; 129(Pt 12): 3224–3237.

16. Leo AAP. Further observations on the spreading depression of activity in the cerebral cortex. *J Neurophysiol* 1947; 10: 409–414.

17. Hossmann KA. Perinifarct depolarizations. *Cerebrovasc Brain Metab Rev* 1996; 8: 195–208.

18. Hossmann K-A. Viability thresholds and the penumbra of focal ischemia. *Ann Neurol* 1994; 36: 557–565.

19. Nakamura H, Strong AJ, Dohmen C, et al. Changes in spreading depression activate and upregulate MMP-9. *Brain* 2010; 133(Pt 7): 1994–2006.

20. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. *Physiol Rev* 2001; 81: 1065–1096.

21. Reifurth C, Alam M, Zahedi-Khorasani M, et al. Na+/K+-ATPase α isoform deficiency results in distinct spreading depolarization phenotypes. *J Cereb Blood Flow Metab* 2020; 40: 622–638.

22. Jordan KG. Emergency EEG and continuous EEG monitoring in acute ischemic stroke. *J Clin Neurophysiol* 2004; 21: 341–352.

23. Kondziella D, Friberg CK, Wellwood I, et al. Continuous EEG monitoring in aneurysmal subarachnoid hemorrhage: a systematic review. *Neurocrit Care* 2015; 22: 450–461.

24. Claassen J, Hirsch LJ, Frontera JA, et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. *Neurocrit Care* 2006; 4: 103–112.

25. Claassen J, Perotte A, Albers D, et al. Nonconvulsive seizures after subarachnoid hemorrhage: multimodal detection and outcomes. *Ann Neurol* 2013; 74: 53–64.

26. Dreier JP, Major S, Punnek H-W, et al. Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex. *Brain* 2012; 135: 259–275.

27. Leung T, Leung H, Soo YOY, et al. The prognosis of acute symptomatic seizures after ischaemic stroke. *J Neurol Neurosurg Psychiatry* 2017; 88: 86–94.

28. Sadeghian H, Lacoste B, Qin T, et al. Spreading depolarizations trigger caveolin-1-dependent endothelial transcytosis. *Ann Neurol* 2018; 84: 409–423.

29. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. *J Clin Invest* 2004; 113: 1447–1455.

30. Prager O, Kamintsky L, Hasam-Henderson LA, et al. Seizure-induced microvascular injury is associated with impaired neurovascular coupling and blood–brain barrier dysfunction. *Epilepsia* 2019; 60: 322–336.

31. Lubinski S, Major S, Kola V, et al. Early blood–brain barrier dysfunction predicts neurological outcome following aneurysmal subarachnoid hemorrhage. *EBioMedicine* 2019; 43: 460–472.

32. Watson BD, Dietrich WD, Bustro R, et al. Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* 1985; 17: 497–504.

33. Dietrich WD, Feng Z-C, Leistra H, et al. Photothrombotic infarction triggers multiple episodes of cortical spreading depression in distant brain regions. *J Cereb Blood Flow Metab* 1994; 14: 20–28.

34. Schoknecht K, Prager O, Vazana U, et al. Monitoring stroke progression: in vivo imaging of cortical perfusion, blood–brain barrier permeability and cellular damage in the rat photothrombosis model. *J Cereb Blood Flow Metab* 2014; 34: 1791–1801.

35. Prager O, Chassidim Y, Klein C, et al. Dynamic in vivo imaging of cerebral blood flow and blood-brain barrier permeability. *NeuroImage* 2010; 49: 337–344.

36. Windmüller O, Lindauer U, Foddis M, et al. Ion changes in spreading ischaemia induce rat middle cerebral artery constriction in the absence of NO. *Brain* 2005; 128(Pt 9): 2042–2051.

37. García JH, Yoshida Y, Chen H, et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. *Am J Pathol* 1993; 142: 623–635.

38. Gundersen HJ, Jensen EB, Kiëu K, et al. The efficiency of systematic sampling in stereology—reconsidered. *J Microsc* 1999; 193(Pt 3): 199–211.

39. Dreier JP, Fabricius M, Ayata C, et al. Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: review and recommendations of the COSBID research group. *J Cereb Blood Flow Metab* 2017; 37: 1595–1625.

40. Sánchez-Porras R, Santos E, Schölz M, et al. The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. *Neuropharmacology* 2014; 84: 52–61.

41. Kao YCJ, Li W, Lai HY, et al. Dynamic perfusion and diffusion MRI of cortical spreading depolarization in photothrombotic ischemia. *Neurobiol Dis* 2014; 71: 131–139.

42. Astrup J, Siesjo BK and Symon L. Thresholds in cerebral ischemia – the ischemic penumbra. *Stroke* 1981; 12: 723–725.
43. Oliveira-Ferreira AI, Winkler MK, Reiffurth C, et al. Spreading depolarization, a pathophysiological mechanism of stroke and migraine aura. *Future Neurol* 2012; 7: 45–64.

44. Balanca B, Meiller A, Bezir, L., et al. Altered hypermetabolic response to cortical spreading depolarizations after traumatic brain injury in rats. *J Cereb Blood Flow Metab* 2017; 37: 1670–1686.

45. van Harreveld A. Changes in the diameter of apical dendrites during spreading depression. *Am J Physiol* 1958; 192: 457–463.

46. van Harreveld A and Ochs S. Cerebral impedance changes after circulatory arrest. *Am J Physiol Content* 1956; 187: 180–192.

47. von Borstel, D., Houben T., Seidel JL, et al. Supply-demand mismatch transients in susceptible peri-infarct hot zones explain the origins of spreading injury depolarizations. *Neuron* 2015; 85: 1117–1131.

48. Major S, Petzold GC, Reiffurth C, et al. A role of the sodium pump in spreading ischemia in rats. *J Cereb Blood Flow Metab* 2017; 37: 1687–1705.

49. Amemori T and Bures J. Ketamine blockade of spreading depolarization: rapid development of tolerance. *Brain Res* 1990; 519: 351–354.

50. Gorelova N, Koroleva V, Amemori T, et al. Ketamine blockade of cortical spreading depression in rats. *Electroencephalogr Clin Neurophysiol* 1987; 66: 440–447.

51. Rashidy-Pour A, Motaghed-Larijani Z and Bures J. Tolerance to ketamine-induced blockade of cortical spreading depression transfers to MK-801 but not to AP5 in rats. *Brain Res* 1995; 693: 64–69.

52. Reinhart KM and Shuttleworth CW. Ketamine reduces deleterious consequences of spreading depolarizations. *Exp Neurol* 2018; 305: 121–128.

53. Sánchez-Porras R, Santos E, Schöll M, et al. Ketamine modulation of the haemodynamic response to spreading depolarization in the gyrencephalic swine brain. *J Cereb Blood Flow Metab* ; 37: 1720–1734.

54. Reeker W, Wernic M, Möllenberg O, et al. High-dose S(+)-ketamine improves neurological outcome following incomplete cerebral ischemia in rats. *Can J Anaesth* 2000; 47: 572–578.

55. Proescholdt M, Heimann A and Kempski O. Neuroprotection of S(+) ketamine isomer in global forebrain ischemia. *Brain Res* 2001; 904: 245–251.

56. Hoffmann U, Sheng H, Ayata C, et al. Anesthesia in experimental stroke research. *Transl Stroke Res* 2016; 7: 358–367.

57. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leão’s cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migraineous aura? *Brain* 2002; 125( Pt 1): 102–112.

58. Gill R, Andiné P, Hillered L, et al. The effect of MK-801 on cortical spreading depression in the penumbral zone following focal ischemia in the rat. *J Cereb Blood Flow Metab* 1992; 12: 371–379.

59. Iijima T, Mies G and Hoßmann KA. Repeated negative DC deflections in rat cortex following middle cerebral artery occlusion are abolished by MK-801: effect on volume of ischemic injury. *J Cereb Blood Flow Metab* 1992; 12: 727–733.

60. Petzold GC, Windmüller O, Haack S, et al. Increased extracellular K+ concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia. *Stroke* 2005; 36: 1270–1277.

61. Yi N-X, Zhou L-Y, Wang X-Y, et al. MK-801 attenuates lesion expansion following acute brain injury in rats: a meta-analysis. *Neural Regen Res* 2019; 14: 1919–1931.

62. Gill R, Brazzell C, Woodruff GN, et al. The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br J Pharmacol 1991; 103: 2030–2036.

63. Dezi L, Greenberg JH, Hamar J, et al. Acute improvement in histological outcome by MK-801 following focal cerebral ischemia and reperfusion in the cat independent of blood flow changes. *J Cereb Blood Flow Metab* 1992; 12: 390–399.

64. Park CK, Nehls DG, Graham DI, et al. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. *Ann Neurol* 1988; 24: 543–551.

65. Roussel S, Pinard E and Seylaz J. Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. *Hypertension* 1992; 19: 40–46.

66. Yao H, Markgraf CG, Dietrich WD, et al. Glutamate antagonist MK-801 attenuates incomplete but not complete infarction in thrombotic distal middle cerebral artery occlusion in Wistar rats. *Brain Res* 1994; 642: 117–122.

67. Buchan A and Pulsinelli WA. Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. *J Neurosci* 1990; 10: 311–316.

68. Koroleva VI, Korolev OS, Loseva E, et al. The effect of MK-801 and of brain-derived polypeptides on the development of ischemic lesion induced by photothrombotic occlusion of the distal middle cerebral artery in rats. *Brain Res* 1998; 786: 104–114.

69. Yao H, Ginsberg MD, Watson BD, et al. Failure of MK-801 to reduce infarct volume in thrombotic middle cerebral artery occlusion in rats. *Stroke* 1993; 24: 864–870; discussion 870–871.

70. Dirmagl U, Tanabe J and Pulsinelli W. Pre- and post-treatment with MK-801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. *Brain Res* 1990; 527: 62–68.

71. Park CK, Nehls DG, Graham DI, et al. Focal cerebral ischemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischemia. *J Cereb Blood Flow Metab* 1988; 8: 757–762.

72. Dickinson R, Peterson BK, Banks P, et al. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. *Anesthesiology* 2007; 107: 756–767.

73. Takagaki M, Feuerstein D, Kumagai T, et al. Isoflurane suppresses cortical spreading depolarizations compared...
to propofol—implications for sedation of neurocritical care patients. *Exp Neurol* 2014; 252: 12–17.
74. Kudo C, Toyama M, Boku A, et al. Anesthetic effects on susceptibility to cortical spreading depression. *Neuropharmacology* 2013; 67: 32–36.
75. Bleilevens C, Roehl AB, Goetzenich A, et al. Effect of anesthesia and cerebral blood flow on neuronal injury in a rat middle cerebral artery occlusion (MCAO) model. *Exp Brain Res* 2013; 224: 155–164.
76. Chang ML, Yang J, Kem S, et al. Nicotinamide and ketamine reduce infarct volume and DNA fragmentation in rats after brain ischemia and reperfusion. *Neurosci Lett* 2002; 322: 137–140.
77. Hernández-Cáceres J, Macías-González R, Brožek G, et al. Systemic ketamine blocks cortical spreading depression but does not delay the onset of terminal anoxic depolarization in rats. *Brain Res* 1987; 437: 360–364.
78. Lauritzen M and Hansen AJ. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. *J Cereb Blood Flow Metab* 1992; 12: 223–229.
79. Madry C, Haglerod C and Attwell D. The role of pannexin hemichannels in the anoxic depolarization of hippocampal pyramidal cells. *Brain* 2010; 133(Pt 12): 3755–3763.
80. Müller M and Somjen GG. Inhibition of major cationic inward currents prevents spreading depression-like hyperpolarization in rat hippocampal tissue slices. *Brain Res* 1998; 812: 1–13.
81. Tyler MW, Yourish HB, Ionescu DF, et al. Classics in chemical neuroscience: ketamine. *ACS Chem Neurosci* 2017; 8: 1122–1134.
82. Klass A, Sánchez-Porras R and Santos E. Systematic review of the pharmacological agents that have been tested against spreading depolarizations. *J Cereb Blood Flow Metab* 2018; 38: 1149–1179.
83. Muir KW and Lees KR. Excitatory amino acid antagonists for acute stroke. *Cochrane Database Syst Rev* 2003; 3: CD001244.
84. Kemp JA and McKernan RM. NMDA receptor pathways as drug targets. *Nat Neurosci* 2002; 5(Suppl): 1039–1042.
85. Sakowitz OW, Kiening KL, Krajewski KL, et al. Preliminary evidence that ketamine inhibits spreading depolarizations in acute human brain injury. *Stroke* 2009; 40: e519–e522.
86. Von der Brelie C, Seifert M, Rot S, et al. Sedation of patients with acute aneurysmal subarachnoid hemorrhage with ketamine is safe and might influence the occurrence of cerebral infarctions associated with delayed cerebral ischemia. *World Neurosurg* 2017; 97: 374–382.
87. Hertle DN, Dreier JP, Woitzik J, et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. *Brain* 2012; 135: 2390–2398.
88. Carlson AP, Abbas M, Alunday RL, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. *J Neurosurg* 2019; 130: 1513–1519.
89. Hartings JA, Ngwenya LB, Carroll CP, et al. Letter to the Editor. Ketamine sedation for the suppression of spreading depolarizations. *J Neurosurg* 2018; 1: 1–2.
90. Schiefecker AJ, Beer R, Pfausler B, et al. Clusters of cortical spreading depolarizations in a patient with intracerebral hemorrhage: a multimodal neuromonitoring study. *Neurocrit Care* 2015; 22: 293–298.
91. Santos E, Olivares-Rivera A, Major S, et al. Lasting s-ketamine block of spreading depolarizations in subarachnoid hemorrhage: a retrospective cohort study. *Crit Care* 2019; 23: 1–14.
92. Drenckhahn C, Windler C, Major S, et al. Complications in aneurysmal subarachnoid hemorrhage patients with and without subdural electrode strip for electrocorticography. *J Clin Neurophysiol* 2016; 33: 250–259.
93. Hartings JA, Williams AJ and Tortella FC. Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia. *Exp Neurol* 2003; 179: 139–149.
94. Lippmann K, Kamistsky L, Kim SY, et al. Epileptiform activity and spreading depolarization in the blood-brain barrier-disrupted peri-infarct hippocampus are associated with impaired GABAergic inhibition and synaptic plasticity. *J Cereb Blood Flow Metab* 2017; 37: 1803–1819.
95. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. *NeuroRx* 2005; 2: 396–409.
96. Arslan G, Alici SK, Ayyildiz M, et al. Interaction between urethane and cannabinoïd CB1 receptor agonist and antagonist in penicillin-induced epileptiform activity. *Acta Neurobiol Exp* 2017; 77: 128–136.
97. Heltovics G, Boda B and Szente M. Anticonvulsive effect of urethane on aminopyridine-induced epileptiform activity. *Neuroreport* 1995; 6: 577–580.
98. Avoli M, Drapeau C, Louvel J, et al. Epileptiform activity induced by low extracellular magnesium in the human cortex maintained in vitro. *Ann Neurol* 1991; 30: 589–596.
99. Borris DJ, Bertram EH and Kapur J. Ketamine controls prolonged status epilepticus. *Epilepsy Res* 2000; 42: 117–122.
100. Croucher M, Collins J and Meldrum B. Anticonvulsant action of excitatory amino acid antagonists. *Science* 1982; 216: 899–901.
101. Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine, are we there yet? *CNS Neurosci Ther* 2013; 19: 411–427.
102. Dorandeu F, Baille V, Mikler J, et al. Protective effects of S+ ketamine and atropine against lethality and brain damage during soman-induced status epilepticus in guinea-pigs. *Toxicology* 2007; 234: 185–193.
103. Szakács R, Weiczner R, Mihály A, et al. Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. *Brain Res Bull* 2003; 59: 485–493.
104. Synowiec AS, Singh DS, Yenugadhati V, et al. Ketamine use in the treatment of refractory status epilepticus. *Epilepsy Res* 2013; 105: 183–188.

105. Prüß H and Holtkamp M. Ketamine successfully terminates malignant status epilepticus. *Epilepsy Res* 2008; 82: 219–222.

106. Holtkamp M. Pharmacotherapy for refractory and super-refractory status epilepticus in adults. *Drugs* 2018; 78: 307–326.

107. van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. *Brain* 2007; 130: 521–534.

108. Sweeney MD, Sagare AP and Zlokovic BV. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat Rev Neurol* 2018; 14: 133–150.

109. Dietrich WD, Busto R, Watson BD, et al. Photochemically induced cerebral infarction. II. Edema and blood-brain barrier disruption. *Acta Neuropathol* 1987; 72: 326–334.

110. Stoll G, Kleinschnitz C, Meuth SG, et al. Transient widespread blood—brain barrier alterations after cerebral photothermolysis as revealed by gadofluorine m-enhanced magnetic resonance imaging. *J Cereb Blood Flow Metab* 2009; 29: 331–341.

111. Belaïev L, Busto R, Zhao W, et al. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. *Brain Res* 1996; 739: 88–96.

112. Stirbian D, Durukan A, Pitkonen M, et al. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. *Neuroscience* 2008; 153: 175–181.

113. Hatashita S, Hoff JT and Salamat SM. Ischemic brain edema and the osmotic gradient between blood and brain. *J Cereb Blood Flow Metab* 1988; 8: 552–559.

114. Knowland D, Arac A, Sekiguchi KJ, et al. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. *Neuron* 2014; 82: 603–617.

115. Nahirney PC, Reeson P and Brown CE. Ultrastructural analysis of blood–brain barrier breakdown in the peri-infarct zone in young adult and aged mice. *J Cereb Blood Flow Metab* 2016; 36: 413–425.

116. Krueger M, Bechmann I, Immig K, et al. Blood–brain barrier breakdown involves four distinct stages of vascular damage in various models of experimental focal cerebral ischemia. *J Cereb Blood Flow Metab* 2015; 35: 292–303.

117. Kang EJ, Major S, Jorks D, et al. Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions. *Neurobiol Dis* 2013; 52: 204–218.

118. Lehmenkühler A, Syková E, Svoboda J, et al. Extracellular space parameters in the rat neocortex and subcortical white matter during postnatal development determined by diffusion analysis. *Neuroscience* 1993; 55: 339–351.